MedTrace Logo

Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder

NCT01108393 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-07-25

No results posted yet for this study

Summary

The study will evaluate the efficacy of agomelatine compared to placebo on the reduction of Obsessive and Compulsive symptoms after 16 weeks of treatment.

Conditions

  • Obsessive Compulsive Disorder

Interventions

DRUG

Agomelatine A

Agomelatine 25 mg film-coated tablet Agomelatine 2x25mg film-coated tablet

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Institut de Recherches Internationales Servier

    lead OTHER

Principal Investigators

  • Joseph Zohar, Prof. · Department of Psychiatry Chaim Sheba Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-08-31
Completion
2013-04-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01108393 on ClinicalTrials.gov